Survey of Ophthalmology
Volume 45 , Pages S243-S249 , May 2001

Relevance of the Site of Injury of Glaucoma to Neuroprotective Strategies

  • Leonard A Levin, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint address: Leonard A. Levin, MD, PhD, University of Wisconsin Medical School, 600 Highland Avenue, Madison, WI 53792 USA

References 

  1. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109:1673–1678[see comments]
  2. Adams RD, Victor M. Principles of Neurology. New York: McGraw-Hill; 1993;
  3. Asman P, Heijl A. Diffuse visual field loss and glaucoma. Acta Ophthalmol (Copenh). 1994;72:303–308
  4. Bianchi-Marzoli S, Rizzo JF, Brancato R, Lessell S. Quantitative analysis of optic disc cupping in compressive optic neuropathy. Ophthalmology. 1995;102:436–440[see comments]
  5. Castillo B, del Cerro M, Breakefield XO, et al.  RGC survival is promoted by genetically modified astrocytes designed to secrete brain-derived neurotrophic factor (BDNF). Brain Res. 1994;647:30–36
  6. Chauhan BC, LeBlanc RP, Shaw AM, et al.  Repeatable diffuse visual field loss in open-angle glaucoma. Ophthalmology. 1997;104:532–538
  7. Drance SM, Douglas GR, Airaksinen PJ, et al.  Diffuse visual field loss in chronic open-angle and low-tension glaucoma. Am J Ophthalmol. 1987;104:577–580
  8. Drance SM, Morgan RW, Sweeney VP. Shock-induced optic neuropathy (a cause of nonprogressive glaucoma). N Engl J Med. 1973;288:392–395
  9. Dreyer EB. A proposed role for excitotoxicity in glaucoma. J Glaucoma. 1998;7:62–67
  10. Heijl A. Lack of diffuse loss of differential light sensitivity in early glaucoma. Acta Ophthalmol (Copenh). 1989;67:353–360
  11. Hernandez MR, Pena JD. The optic nerve head in glaucomatous optic neuropathy. Arch Ophthalmol. 1997;115:389–395
  12. Hoyt WF, Luis O. Visual fiber anatomy in the infrageniculate pathway of the primate. Arch Ophthalmol. 1962;68:124–136
  13. Kline LB, Glaser JS. Dominant optic atrophy. The clinical profile. Arch Ophthalmol. 1979;97:1680–1686
  14. Levin LA. Biology of the optic nerve. In:  Albert DM,  Jakobieck FA editor. Principles and Practice of Ophthalmology. Philadelphia: WB Saunders; 2000;p. 3890–3906
  15. Malpeli JG, Baker FH. The representation of the visual field in the lateral geniculate nucleus of Macaca mulatta. J Comp Neurol. 1975;161:569–594
  16. Malpeli JG, Lee D, Baker FH. Laminar and retinotopic organization of the macaque lateral geniculate nucleus (magnocellular and parvocellular magnification functions). J Comp Neurol. 1996;375:363–377
  17. Mansour-Robaey S, Clarke DB, Wang YC, et al.  Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized RGCs. Proc Natl Acad Sci USA. 1994;91:1632–1636
  18. Mutlukan E. Diffuse and localised visual field defects to automated perimetry in primary open angle glaucoma. Eye. 1995;9:745–750
  19. Naito J. Retinogeniculate projection fibers in the monkey optic nerve (a demonstration of the fiber pathways by retrograde axonal transport of WGA-HRP). J Comp Neurol. 1989;284:174–186
  20. Neufeld AH. Nitric oxide (a potential mediator of RGC damage in glaucoma). Surv Ophthalmol. 1999;43(Suppl 1):S129–S135
  21. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115:497–503
  22. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of RGCs in a rat model of chronic glaucoma. Proc Natl Acad Sci USA. 1999;96:9944–9948
  23. Newman SA, Miller NR. Optic tract syndrome. Neuro-ophthalmologic considerations. Arch Ophthalmol. 1983;101:1241–1250
  24. Peinado-Ramon P, Salvador M, Villegas-Perez MP, Vidal-Sanz M. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat RGCs. A quantitative in vivo study. Invest Ophthalmol Vis Sci. 1996;37:489–500
  25. Quigley HA. Ganglion cell death in glaucoma (pathology recapitulates ontogeny). Aust NZ J Ophthalmol. 1995;23:85–91
  26. Schwartz M, Belkin M, Yoles E, Solomon A. Potential treatment modalities for glaucomatous neuropathy (neuroprotection and neuroregeneration). J Glaucoma. 1996;5:427–432
  27. Schwartz M, Yoles E, Levin LA. Axogenic and somagenic neurodegenerative diseases (definitions and therapeutic implications). Mol Med Today. 1999;5:470–473
  28. Sharma M, Volpe NJ, Dreyer EB. Methanol-induced optic nerve cupping. Arch Ophthalmol. 1999;117:286
  29. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in RGCs. Vision Res. 1997;37:3483–3493
  30. Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma?. Arch Ophthalmol. 1999;117:1540–1544
  31. Wen R, Cheng T, Li Y, et al.  Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci. 1996;16:5986–5992
  32. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40:65–73
  33. Yucel YH, Zhang Q, Gupta N, et al.  Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol. 2000;118:378–384

PII: S0039-6257(01)00197-7

Survey of Ophthalmology
Volume 45 , Pages S243-S249 , May 2001

Article Tools

* Image Usage & Resolution